Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated ...

Hanoi (VNA) - Prime Minister Pham Minh Chinh on October 20 signed a decision on the establishment of the National Steering ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guide ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor ...

After 5 years, Kisqali ® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Data also show a 29.1% risk reduction in distant ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...

German investigators have carried out raids in relation to Northern Data AG, the Frankfurt-listed technology firm backed by stablecoin issuer Tether Holdings Ltd. that has been moving away from crypto ...